1. Cardiac Toxicity in Operable Esophageal Cancer Patients Treated With or Without Chemoradiation
- Author
-
Aleksandra Kuczmarska-Haas, Jacob S. Witt, Menggang Yu, James D. Maloney, Justin C. Jagodinsky, Yifei Liu, Andrew M. Baschnagel, Poonam Yadav, Michael F. Bassetti, and Mark A. Ritter
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Esophageal Neoplasms ,Heart Diseases ,Severity of Illness Index ,Article ,Pericardial Effusion ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,medicine ,Humans ,Cumulative incidence ,030212 general & internal medicine ,Survival rate ,Aged ,Retrospective Studies ,Aged, 80 and over ,Univariate analysis ,business.industry ,Incidence ,Hazard ratio ,Dose fractionation ,Common Terminology Criteria for Adverse Events ,Chemoradiotherapy, Adjuvant ,Esophageal cancer ,Middle Aged ,medicine.disease ,Neoadjuvant Therapy ,Esophagectomy ,Survival Rate ,Oncology ,030220 oncology & carcinogenesis ,Cardiology ,cardiovascular system ,Female ,Dose Fractionation, Radiation ,Radiotherapy, Intensity-Modulated ,business ,Chemoradiotherapy - Abstract
PURPOSE The purpose of this study was to evaluate predictors of cardiac events in esophageal cancer patients treated with neoadjuvant chemoradiotherapy (NA CRT) followed by surgery compared with surgery alone. MATERIALS AND METHODS We retrospectively identified patients treated for esophageal cancer between 2006 and 2016. A total of 123 patients were identified; 70 were treated with surgery alone, and 53 were treated with NA CRT. Cardiac events were scored based on Common Terminology Criteria for Adverse Events (version 4.03), and dosimetric data was compiled for all patients who received radiation. Univariate analysis and multivariable analysis (MVA) were performed to identify predictors of cardiac events. Competing risk of death regression was performed to a model the cumulative incidence of cardiac events. RESULTS The overall rates of grade ≥3 cardiac events were 24.5% in the NA CRT group versus 10% in the surgery group (P=0.04). On MVA, use of NA CRT (P
- Published
- 2019